Celgene Corpor…
ProfileJobs (448)

Celgene Corporation

Suggest Edit
    • Healthcarebiotechdrug developmenthealthtechlife sciencesoncologypharmatherapy
    Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
    Revenue(FY, 2017)
    $13 B
    Market capitalization(2018-09-21)
    $61.7 B
    TypePublic
    HQSummit, US
    Founded1986
    Size (employees)7,467 (est)+5%
    Websitecelgene.com
    Celgene Corporation was founded in 1986 and is headquartered in Summit, US
    Report incorrect company information

    Viewing summary data as a guest

    Sign up for free to see all data

    Key People/Management at Celgene Corporation

    Mark J. Alles

    Mark J. Alles

    Chairman and Chief Executive Officer
    Peter N. Kellogg

    Peter N. Kellogg

    Executive Vice President and Chief Financial Officer
    Nadim Ahmed

    Nadim Ahmed

    President, Hematology & Oncology
    Terrie Curran

    Terrie Curran

    President, Inflammation and Immunology
    Rupert Vessey

    Rupert Vessey

    Executive Vice President and President, Research and Early Development
    Jonathan Biller

    Jonathan Biller

    Executive Vice President and General Counsel
    Show more

    Celgene Corporation Office Locations

    Celgene Corporation has offices in Singapore, Summit and Boudry
    Summit, US (HQ)
    86 Morris Avenue Summit
    Singapore, SG
    200 Newton Road #04-01, Newton 200
    Boudry, CH
    Route de Perreux 1
    Show all (3)
    Report incorrect company information

    Celgene Corporation Financials and Metrics

    Celgene Corporation Revenue

    Embed Graph
    Celgene Corporation's revenue was reported to be $13 b in FY, 2017
    USD

    Revenue (Q2, 2018)

    		7.4 b

    Gross profit (Q2, 2018)

    		7.1 b

    Gross profit margin (Q2, 2018), %

    		96.4%

    Net income (Q2, 2018)

    		1.9 b

    EBIT (Q2, 2018)

    		1.7 b

    Market capitalization (21-Sep-2018)

    		61.7 b

    Closing stock price (21-Sep-2018)

    		87.7

    Cash (30-Jun-2018)

    		1.5 b

    EV

    		61.7 b
    Celgene Corporation's current market capitalization is $61.7 b.
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Revenue

    		6.5 b7.7 b9.3 b11.2 b13 b

    Revenue growth, %

    		18%21%21%

    Cost of goods sold

    		340.4 m385.9 m420.1 m438 m461 m

    Gross profit

    		6.2 b7.3 b8.8 b10.8 b12.5 b
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

    Revenue

    		2.3 b2.3 b2.5 b2.8 b3 b3 b3.3 b3.3 b3.5 b7.4 b

    Cost of goods sold

    		100.8 m109.9 m105.9 m110.9 m107.7 m113 m111 m118 m135 m261 m

    Gross profit

    		2.2 b2.2 b2.4 b2.6 b2.9 b2.8 b3.2 b3.2 b3.4 b7.1 b

    Gross profit Margin, %

    		96%95%96%96%96%96%97%96%96%96%
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Cash

    		3.2 b4.1 b4.9 b6.2 b7 b

    Inventories

    		340.4 m393.1 m443.4 m497.9 m541 m

    Current Assets

    		7.6 b9.7 b9.4 b10.9 b14.9 b

    PP&E

    		593.4 m642.6 m814.1 m929.8 m1.1 b
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

    Cash

    		2.4 b2.4 b3.2 b3.7 b4.4 b4.5 b6 b4.4 b5.1 b5.5 b5.3 b6.7 b5.5 b2.8 b1.5 b

    Inventories

    		313.3 m347.8 m360 m372 m386.7 m414.3 m420.9 m470.6 m490.4 m507.9 m509 m533 m537 m536 m555 m

    Current Assets

    		7.6 b6.9 b8.1 b8.8 b9.7 b9.9 b10.2 b8.4 b9.2 b9.6 b11.6 b13.1 b14.8 b7.9 b6.9 b

    PP&E

    		592.3 m595.7 m605.1 m623.6 m649.7 m675.2 m702 m840 m854 m891.3 m958 m989 m1 b1.3 b1.3 b
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		1.4 b2 b1.6 b2 b2.9 b

    Depreciation and Amortization

    		134 m

    Inventories

    		(89.7 m)(56.5 m)(50.6 m)(55.3 m)(42 m)

    Cash From Operating Activities

    		2.2 b2.8 b2.5 b4 b5.2 b
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

    Net Income

    		1.2 b279.7 m877.5 m1.4 b718.9 m1.1 b1 b800.7 m1.4 b1.6 b941 m2 b3 b846 m1.9 b

    Depreciation and Amortization

    		71.8 m25.5 m52.1 m78.1 m28.1 m57.8 m86.6 m29.2 m58.5 m89.6 m32 m66 m100 m126 m296 m

    Inventories

    		(62.6 m)(7 m)(19.1 m)(33.6 m)7.3 m(19.2 m)(27.1 m)(25.6 m)(45.2 m)(62.3 m)(10 m)(32 m)(37 m)6 m(14 m)

    Cash From Operating Activities

    		1.7 b557.1 m1.1 b2 b856.5 m1.1 b1.4 b974.9 m1.9 b2.6 b853 m2.5 b3.6 b(325 m)904 m
    show all
    USDY, 2018

    EV/EBIT

    		36.2 x

    EV/CFO

    		68.2 x

    EV/FCF

    		83.8 x

    Financial Leverage

    		9.8 x
    Show all financial metrics

    Celgene Corporation Operating Metrics

    FY, 2016

    Active Clinical Studies

    		52
    Show all operating metrics

    Celgene Corporation Acquisitions / Subsidiaries

    Acquired CompanyDateDeal Size
    Juno TherapeuticsJanuary 22, 2018$9 b
    Impact BiomedicinesJanuary 07, 2018
    Report incorrect company information

    Competitors

    Shire
    Healthcare - Public
    Amgen
    Healthcare - Public
    Gilead Sciences
    Healthcare - Public
    Sanofi
    Healthcare - Public
    Regeneron Pharmaceuticals
    Healthcare - Public
    Compare competitors

    Celgene Corporation Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    Celgene Corporation Company Life and Culture

    Report incorrect company information
    Download PDF